Hemodynamic effects of nitric oxide synthase inhibition at steady state and following tumor necrosis factor-α-induced myodepression

Nitric oxide (NO) has been proposed as a common mediator of tumor necrosis factor-alpha (TNF alpha)-induced vasodilation and myocardial dysfunction. Accordingly, we performed an extensive assessment of the influence of NO synthase inhibition on left ventricle (LV) and circulatory performance in cons...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cardiovascular research 1999-12, Vol.44 (3), p.527-535
Hauptverfasser: MURRAY, D. R, PRABHU, S. D, FREEMAN, G. L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 535
container_issue 3
container_start_page 527
container_title Cardiovascular research
container_volume 44
creator MURRAY, D. R
PRABHU, S. D
FREEMAN, G. L
description Nitric oxide (NO) has been proposed as a common mediator of tumor necrosis factor-alpha (TNF alpha)-induced vasodilation and myocardial dysfunction. Accordingly, we performed an extensive assessment of the influence of NO synthase inhibition on left ventricle (LV) and circulatory performance in conscious dogs at steady state and after establishment of TNF alpha mediated myodepression. Autonomically blocked, chronically instrumented dogs were studied at steady state and 6 h after initiation of a 1-h rhTNF alpha infusion (40 micrograms/kg). Ventricular performance was evaluated using the pressure-volume framework. Dogs were then treated with either NG-nitro-L-arginine methylester (L-NAME, 40 mg/kg bolus) or angiotensin II (250-500 ng/kg). L-NAME, under control conditions or following recombinant human (rh) TNF alpha-induced ventricular dysfunction, produced marked increases in afterload with attendant increases in LV pressure, volume, and prolonged isovolumic relaxation without adversely influencing coronary blood flow. regardless of whether the dogs received rhTNF alpha, L-NAME did not affect the slopes of the end-systolic pressure-volume and stroke-work (SW)-end-diastolic volume (EDV) relations (force-based measure of contractility), whereas the slope of the dP/dtmax-EDV relation, a velocity dependent parameter of LV systolic function, declined. Overall ventricular performance, as seen by the circulation, was reduced by L-NAME in control as well as rhTNF alpha-treated dogs, evidenced by rightward shifts of the SW-EDV and dP/dtmax-EDV relations. Similar findings were observed in the separate cohorts of dogs, at steady state and 6 h after rhTNF alpha, following angiotensin II at matched systolic pressure. Systemic NO synthase inhibition with L-NAME does not acutely reverse rhTNF alpha-induced myocardial dysfunction. The detrimental influence of L-NAME on LV size, relaxation, and velocity-based measures of contractility is likely attributable to its effects on increasing afterload.
doi_str_mv 10.1016/S0008-6363(99)00226-6
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69441099</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69441099</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-5ea03689367b3045906d63f63ed5cd2bb0011807a4d965554037ff6e9b482a1b3</originalsourceid><addsrcrecordid>eNpNkE2O1DAQRi0EYpqGI4C8QAgWgXIcO_ESjYBBGokFsLYcu8wYJXZjO4LsuRAX4Uykp1vAqvSVXv3oEfKYwUsGTL76CABDI7nkz5V6AdC2spF3yI71QjS87cRdsvuLXJAHpXzdohB9d59cMJAK2qHbkZ9XOCe3RjMHS9F7tLXQ5GkMNW-d9CM4pGWN9cYUpCHehDHUkCI1lZaKxq1bMRWpiY76NE3pe4hfaF3mlGlEm1MJhXpja8rN719NiG6x6Oi8JoeHjKVsyx6Se95MBR-d6558fvvm0-VVc_3h3fvL19eN5QOrjUADXA6Ky37k0AkF0knuJUcnrGvHEYCxAXrTOSWFEB3w3nuJauyG1rCR78mz095DTt8WLFXPoVicJhMxLUVL1XUMlNpAcQKP_5eMXh9ymE1eNQN91K9v9eujW62UvtW_pT15cj6wjDO6_6ZOvjfg6RkwxZrJZxNtKP-4FlrRSv4HWkeQNg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69441099</pqid></control><display><type>article</type><title>Hemodynamic effects of nitric oxide synthase inhibition at steady state and following tumor necrosis factor-α-induced myodepression</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>MURRAY, D. R ; PRABHU, S. D ; FREEMAN, G. L</creator><creatorcontrib>MURRAY, D. R ; PRABHU, S. D ; FREEMAN, G. L</creatorcontrib><description>Nitric oxide (NO) has been proposed as a common mediator of tumor necrosis factor-alpha (TNF alpha)-induced vasodilation and myocardial dysfunction. Accordingly, we performed an extensive assessment of the influence of NO synthase inhibition on left ventricle (LV) and circulatory performance in conscious dogs at steady state and after establishment of TNF alpha mediated myodepression. Autonomically blocked, chronically instrumented dogs were studied at steady state and 6 h after initiation of a 1-h rhTNF alpha infusion (40 micrograms/kg). Ventricular performance was evaluated using the pressure-volume framework. Dogs were then treated with either NG-nitro-L-arginine methylester (L-NAME, 40 mg/kg bolus) or angiotensin II (250-500 ng/kg). L-NAME, under control conditions or following recombinant human (rh) TNF alpha-induced ventricular dysfunction, produced marked increases in afterload with attendant increases in LV pressure, volume, and prolonged isovolumic relaxation without adversely influencing coronary blood flow. regardless of whether the dogs received rhTNF alpha, L-NAME did not affect the slopes of the end-systolic pressure-volume and stroke-work (SW)-end-diastolic volume (EDV) relations (force-based measure of contractility), whereas the slope of the dP/dtmax-EDV relation, a velocity dependent parameter of LV systolic function, declined. Overall ventricular performance, as seen by the circulation, was reduced by L-NAME in control as well as rhTNF alpha-treated dogs, evidenced by rightward shifts of the SW-EDV and dP/dtmax-EDV relations. Similar findings were observed in the separate cohorts of dogs, at steady state and 6 h after rhTNF alpha, following angiotensin II at matched systolic pressure. Systemic NO synthase inhibition with L-NAME does not acutely reverse rhTNF alpha-induced myocardial dysfunction. The detrimental influence of L-NAME on LV size, relaxation, and velocity-based measures of contractility is likely attributable to its effects on increasing afterload.</description><identifier>ISSN: 0008-6363</identifier><identifier>EISSN: 1755-3245</identifier><identifier>DOI: 10.1016/S0008-6363(99)00226-6</identifier><identifier>PMID: 10690284</identifier><identifier>CODEN: CVREAU</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Analysis of Variance ; Angiotensin II - pharmacology ; Animals ; Biological and medical sciences ; Blood Pressure - drug effects ; Dogs ; Enzyme Inhibitors - pharmacology ; Female ; Fundamental and applied biological sciences. Psychology ; Heart ; Hemodynamics - drug effects ; Male ; Myocardial Contraction - drug effects ; NG-Nitroarginine Methyl Ester - pharmacology ; Nitric Oxide Synthase - antagonists &amp; inhibitors ; Stroke Volume - drug effects ; Tumor Necrosis Factor-alpha - pharmacology ; Ventricular Pressure - drug effects ; Vertebrates: cardiovascular system</subject><ispartof>Cardiovascular research, 1999-12, Vol.44 (3), p.527-535</ispartof><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c381t-5ea03689367b3045906d63f63ed5cd2bb0011807a4d965554037ff6e9b482a1b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1202526$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10690284$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MURRAY, D. R</creatorcontrib><creatorcontrib>PRABHU, S. D</creatorcontrib><creatorcontrib>FREEMAN, G. L</creatorcontrib><title>Hemodynamic effects of nitric oxide synthase inhibition at steady state and following tumor necrosis factor-α-induced myodepression</title><title>Cardiovascular research</title><addtitle>Cardiovasc Res</addtitle><description>Nitric oxide (NO) has been proposed as a common mediator of tumor necrosis factor-alpha (TNF alpha)-induced vasodilation and myocardial dysfunction. Accordingly, we performed an extensive assessment of the influence of NO synthase inhibition on left ventricle (LV) and circulatory performance in conscious dogs at steady state and after establishment of TNF alpha mediated myodepression. Autonomically blocked, chronically instrumented dogs were studied at steady state and 6 h after initiation of a 1-h rhTNF alpha infusion (40 micrograms/kg). Ventricular performance was evaluated using the pressure-volume framework. Dogs were then treated with either NG-nitro-L-arginine methylester (L-NAME, 40 mg/kg bolus) or angiotensin II (250-500 ng/kg). L-NAME, under control conditions or following recombinant human (rh) TNF alpha-induced ventricular dysfunction, produced marked increases in afterload with attendant increases in LV pressure, volume, and prolonged isovolumic relaxation without adversely influencing coronary blood flow. regardless of whether the dogs received rhTNF alpha, L-NAME did not affect the slopes of the end-systolic pressure-volume and stroke-work (SW)-end-diastolic volume (EDV) relations (force-based measure of contractility), whereas the slope of the dP/dtmax-EDV relation, a velocity dependent parameter of LV systolic function, declined. Overall ventricular performance, as seen by the circulation, was reduced by L-NAME in control as well as rhTNF alpha-treated dogs, evidenced by rightward shifts of the SW-EDV and dP/dtmax-EDV relations. Similar findings were observed in the separate cohorts of dogs, at steady state and 6 h after rhTNF alpha, following angiotensin II at matched systolic pressure. Systemic NO synthase inhibition with L-NAME does not acutely reverse rhTNF alpha-induced myocardial dysfunction. The detrimental influence of L-NAME on LV size, relaxation, and velocity-based measures of contractility is likely attributable to its effects on increasing afterload.</description><subject>Analysis of Variance</subject><subject>Angiotensin II - pharmacology</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Dogs</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Heart</subject><subject>Hemodynamics - drug effects</subject><subject>Male</subject><subject>Myocardial Contraction - drug effects</subject><subject>NG-Nitroarginine Methyl Ester - pharmacology</subject><subject>Nitric Oxide Synthase - antagonists &amp; inhibitors</subject><subject>Stroke Volume - drug effects</subject><subject>Tumor Necrosis Factor-alpha - pharmacology</subject><subject>Ventricular Pressure - drug effects</subject><subject>Vertebrates: cardiovascular system</subject><issn>0008-6363</issn><issn>1755-3245</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkE2O1DAQRi0EYpqGI4C8QAgWgXIcO_ESjYBBGokFsLYcu8wYJXZjO4LsuRAX4Uykp1vAqvSVXv3oEfKYwUsGTL76CABDI7nkz5V6AdC2spF3yI71QjS87cRdsvuLXJAHpXzdohB9d59cMJAK2qHbkZ9XOCe3RjMHS9F7tLXQ5GkMNW-d9CM4pGWN9cYUpCHehDHUkCI1lZaKxq1bMRWpiY76NE3pe4hfaF3mlGlEm1MJhXpja8rN719NiG6x6Oi8JoeHjKVsyx6Se95MBR-d6558fvvm0-VVc_3h3fvL19eN5QOrjUADXA6Ky37k0AkF0knuJUcnrGvHEYCxAXrTOSWFEB3w3nuJauyG1rCR78mz095DTt8WLFXPoVicJhMxLUVL1XUMlNpAcQKP_5eMXh9ymE1eNQN91K9v9eujW62UvtW_pT15cj6wjDO6_6ZOvjfg6RkwxZrJZxNtKP-4FlrRSv4HWkeQNg</recordid><startdate>19991201</startdate><enddate>19991201</enddate><creator>MURRAY, D. R</creator><creator>PRABHU, S. D</creator><creator>FREEMAN, G. L</creator><general>Oxford University Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19991201</creationdate><title>Hemodynamic effects of nitric oxide synthase inhibition at steady state and following tumor necrosis factor-α-induced myodepression</title><author>MURRAY, D. R ; PRABHU, S. D ; FREEMAN, G. L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-5ea03689367b3045906d63f63ed5cd2bb0011807a4d965554037ff6e9b482a1b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Analysis of Variance</topic><topic>Angiotensin II - pharmacology</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Dogs</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Heart</topic><topic>Hemodynamics - drug effects</topic><topic>Male</topic><topic>Myocardial Contraction - drug effects</topic><topic>NG-Nitroarginine Methyl Ester - pharmacology</topic><topic>Nitric Oxide Synthase - antagonists &amp; inhibitors</topic><topic>Stroke Volume - drug effects</topic><topic>Tumor Necrosis Factor-alpha - pharmacology</topic><topic>Ventricular Pressure - drug effects</topic><topic>Vertebrates: cardiovascular system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MURRAY, D. R</creatorcontrib><creatorcontrib>PRABHU, S. D</creatorcontrib><creatorcontrib>FREEMAN, G. L</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cardiovascular research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MURRAY, D. R</au><au>PRABHU, S. D</au><au>FREEMAN, G. L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hemodynamic effects of nitric oxide synthase inhibition at steady state and following tumor necrosis factor-α-induced myodepression</atitle><jtitle>Cardiovascular research</jtitle><addtitle>Cardiovasc Res</addtitle><date>1999-12-01</date><risdate>1999</risdate><volume>44</volume><issue>3</issue><spage>527</spage><epage>535</epage><pages>527-535</pages><issn>0008-6363</issn><eissn>1755-3245</eissn><coden>CVREAU</coden><abstract>Nitric oxide (NO) has been proposed as a common mediator of tumor necrosis factor-alpha (TNF alpha)-induced vasodilation and myocardial dysfunction. Accordingly, we performed an extensive assessment of the influence of NO synthase inhibition on left ventricle (LV) and circulatory performance in conscious dogs at steady state and after establishment of TNF alpha mediated myodepression. Autonomically blocked, chronically instrumented dogs were studied at steady state and 6 h after initiation of a 1-h rhTNF alpha infusion (40 micrograms/kg). Ventricular performance was evaluated using the pressure-volume framework. Dogs were then treated with either NG-nitro-L-arginine methylester (L-NAME, 40 mg/kg bolus) or angiotensin II (250-500 ng/kg). L-NAME, under control conditions or following recombinant human (rh) TNF alpha-induced ventricular dysfunction, produced marked increases in afterload with attendant increases in LV pressure, volume, and prolonged isovolumic relaxation without adversely influencing coronary blood flow. regardless of whether the dogs received rhTNF alpha, L-NAME did not affect the slopes of the end-systolic pressure-volume and stroke-work (SW)-end-diastolic volume (EDV) relations (force-based measure of contractility), whereas the slope of the dP/dtmax-EDV relation, a velocity dependent parameter of LV systolic function, declined. Overall ventricular performance, as seen by the circulation, was reduced by L-NAME in control as well as rhTNF alpha-treated dogs, evidenced by rightward shifts of the SW-EDV and dP/dtmax-EDV relations. Similar findings were observed in the separate cohorts of dogs, at steady state and 6 h after rhTNF alpha, following angiotensin II at matched systolic pressure. Systemic NO synthase inhibition with L-NAME does not acutely reverse rhTNF alpha-induced myocardial dysfunction. The detrimental influence of L-NAME on LV size, relaxation, and velocity-based measures of contractility is likely attributable to its effects on increasing afterload.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>10690284</pmid><doi>10.1016/S0008-6363(99)00226-6</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0008-6363
ispartof Cardiovascular research, 1999-12, Vol.44 (3), p.527-535
issn 0008-6363
1755-3245
language eng
recordid cdi_proquest_miscellaneous_69441099
source MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Analysis of Variance
Angiotensin II - pharmacology
Animals
Biological and medical sciences
Blood Pressure - drug effects
Dogs
Enzyme Inhibitors - pharmacology
Female
Fundamental and applied biological sciences. Psychology
Heart
Hemodynamics - drug effects
Male
Myocardial Contraction - drug effects
NG-Nitroarginine Methyl Ester - pharmacology
Nitric Oxide Synthase - antagonists & inhibitors
Stroke Volume - drug effects
Tumor Necrosis Factor-alpha - pharmacology
Ventricular Pressure - drug effects
Vertebrates: cardiovascular system
title Hemodynamic effects of nitric oxide synthase inhibition at steady state and following tumor necrosis factor-α-induced myodepression
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T00%3A02%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hemodynamic%20effects%20of%20nitric%20oxide%20synthase%20inhibition%20at%20steady%20state%20and%20following%20tumor%20necrosis%20factor-%CE%B1-induced%20myodepression&rft.jtitle=Cardiovascular%20research&rft.au=MURRAY,%20D.%20R&rft.date=1999-12-01&rft.volume=44&rft.issue=3&rft.spage=527&rft.epage=535&rft.pages=527-535&rft.issn=0008-6363&rft.eissn=1755-3245&rft.coden=CVREAU&rft_id=info:doi/10.1016/S0008-6363(99)00226-6&rft_dat=%3Cproquest_cross%3E69441099%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69441099&rft_id=info:pmid/10690284&rfr_iscdi=true